AR111426A1 - Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf - Google Patents

Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf

Info

Publication number
AR111426A1
AR111426A1 ARP180101067A ARP180101067A AR111426A1 AR 111426 A1 AR111426 A1 AR 111426A1 AR P180101067 A ARP180101067 A AR P180101067A AR P180101067 A ARP180101067 A AR P180101067A AR 111426 A1 AR111426 A1 AR 111426A1
Authority
AR
Argentina
Prior art keywords
imidazol
modulators
tnf activity
derivatives fused
pentacyclic
Prior art date
Application number
ARP180101067A
Other languages
English (en)
Inventor
Zhaoning Zhu
Mengyang Xuan
Malcolm Maccoss
James Andrew Johnson
Martin Clive Hutchings
Helen Tracey Horsley
Yann Foricher
Haro Garcia Teresa De
Daniel Christopher Brookings
Original Assignee
Ucb Biopharma Sprl
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl, Sanofi Sa filed Critical Ucb Biopharma Sprl
Publication of AR111426A1 publication Critical patent/AR111426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde X representa N o C-F; R¹ representa hidrógeno o metilo; R² representa hidrógeno, metilo o trifluorometilo; y R³ representa hidrógeno, ciano, hidroxilo o hidroximetilo.
ARP180101067A 2017-04-25 2018-04-25 Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf AR111426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25

Publications (1)

Publication Number Publication Date
AR111426A1 true AR111426A1 (es) 2019-07-10

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101067A AR111426A1 (es) 2017-04-25 2018-04-25 Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf

Country Status (34)

Country Link
US (3) US10980814B2 (es)
EP (2) EP3939980B1 (es)
JP (2) JP7083358B2 (es)
KR (1) KR102565132B1 (es)
CN (1) CN110582495B (es)
AR (1) AR111426A1 (es)
AU (1) AU2018259040B2 (es)
BR (1) BR112019020314A2 (es)
CA (1) CA3058980A1 (es)
CL (1) CL2019002875A1 (es)
CO (1) CO2019012856A2 (es)
CR (1) CR20190526A (es)
DK (1) DK3615534T3 (es)
EA (1) EA039049B1 (es)
ES (2) ES2956555T3 (es)
HR (1) HRP20211927T1 (es)
HU (1) HUE056593T2 (es)
IL (1) IL269890B (es)
LT (1) LT3615534T (es)
MA (2) MA49055B1 (es)
MX (1) MX2019012443A (es)
MY (1) MY197212A (es)
NZ (1) NZ758198A (es)
PE (1) PE20200662A1 (es)
PH (1) PH12019502182A1 (es)
PL (2) PL3939980T3 (es)
PT (2) PT3939980T (es)
RS (1) RS62596B1 (es)
SG (1) SG11201908871SA (es)
SI (1) SI3615534T1 (es)
TW (1) TWI801378B (es)
UY (1) UY37700A (es)
WO (1) WO2018197503A1 (es)
ZA (1) ZA201906255B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968089B2 (ja) * 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合六環式イミダゾール誘導体
WO2020084008A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MA40770B1 (fr) * 2014-10-03 2021-11-30 Sanofi Sa Dérivés d'imidazoles pentacyclic fusionnés
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling

Also Published As

Publication number Publication date
ES2893807T3 (es) 2022-02-10
JP7083358B2 (ja) 2022-06-10
LT3615534T (lt) 2021-11-25
WO2018197503A1 (en) 2018-11-01
CL2019002875A1 (es) 2020-03-06
HRP20211927T1 (hr) 2022-03-18
US20200046723A1 (en) 2020-02-13
CN110582495B (zh) 2022-04-01
EP3939980A1 (en) 2022-01-19
CA3058980A1 (en) 2018-11-01
KR20190141200A (ko) 2019-12-23
MA49055A (fr) 2021-05-05
ZA201906255B (en) 2021-01-27
HUE056593T2 (hu) 2022-02-28
TW201841918A (zh) 2018-12-01
EP3939980B1 (en) 2023-07-26
AU2018259040B2 (en) 2022-04-28
NZ758198A (en) 2024-01-26
CR20190526A (es) 2020-01-07
PL3615534T3 (pl) 2022-01-31
PT3615534T (pt) 2021-10-21
CN110582495A (zh) 2019-12-17
RS62596B1 (sr) 2021-12-31
KR102565132B1 (ko) 2023-08-08
TWI801378B (zh) 2023-05-11
UY37700A (es) 2018-11-30
ES2956555T3 (es) 2023-12-22
IL269890B (en) 2022-03-01
EP3615534B1 (en) 2021-09-15
US20230250105A1 (en) 2023-08-10
PE20200662A1 (es) 2020-06-11
MY197212A (en) 2023-06-01
DK3615534T3 (da) 2021-10-18
US20210252012A1 (en) 2021-08-19
EA201992407A1 (ru) 2020-04-06
JP7299382B2 (ja) 2023-06-27
BR112019020314A2 (pt) 2020-04-28
AU2018259040A1 (en) 2019-10-31
PL3939980T3 (pl) 2024-02-05
CO2019012856A2 (es) 2020-01-17
US10980814B2 (en) 2021-04-20
MA49055B1 (fr) 2021-12-31
MX2019012443A (es) 2020-01-13
PH12019502182A1 (en) 2020-06-08
EP3615534A1 (en) 2020-03-04
SG11201908871SA (en) 2019-10-30
JP2020517637A (ja) 2020-06-18
JP2022116233A (ja) 2022-08-09
EA039049B1 (ru) 2021-11-26
MA57699B1 (fr) 2023-11-30
PT3939980T (pt) 2023-08-07
SI3615534T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
CL2015002279A1 (es) Amidas heterocíclicas como inhibidores de cinasas
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
CR20150520A (es) 4-amino-6-(heterocíclico)picolinatos y 6-amino-amino-2-(heterocíclico) pirimidin -4-carboxilatos y su uso como herbicidas
AR073327A1 (es) Heterociclos nitrogenados y su uso como anticancerigenos
AR112333A1 (es) Pirrolopirimidina y derivados de pirrolopirimidina
HN2011003097A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
AR101392A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR094959A1 (es) Compuestos de imidazo piridina
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
PH12018500316A1 (en) Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
PE20150182A1 (es) Compuestos de fenoxietil piperidina
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
AR111414A1 (es) Derivados de heteroarilcarboxamida como inhibidores de la calicreína plasmática
AR111426A1 (es) Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf